Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
ANI Pharmaceuticals Inc Market Cap
The ANI Pharmaceuticals Inc (ANIP) share price is expected to increase by 35.1% over the next year. This is based on calculating the average 12-month share price estimate provided by 5 stock analysts who have covered ANIP. Price targets range from $62 at the low end to $94 at the high end. The current analyst consensus for ANIP is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
ANI Pharmaceuticals Inc has a total of 5 Wall St Analyst ratings. There are 4 buy ratings, 1 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that ANI Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of ANIP.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Oren Livnat HC Wainwright & Co. | Buy | $94 | Reiterates | Nov 11, 2024 |
| Gregory Fraser Truist Securities | Hold | $62 | Maintains | Oct 22, 2024 |
| David Amsellem Piper Sandler | Overweight | $68 | Initiates | Oct 11, 2024 |
| Elliot Wilbur Raymond James | Outperform | $83 | Maintains | Sep 18, 2024 |
| Oren Livnat HC Wainwright & Co. | Buy | $94 | Reiterates | Sep 17, 2024 |
| Gregory Fraser Truist Securities | Hold | $60 | Downgrade | Sep 11, 2024 |
| Oren Livnat HC Wainwright & Co. | Buy | $94 | Reiterates | Aug 7, 2024 |
| Oren Livnat HC Wainwright & Co. | Buy | $94 | Maintains | Jun 26, 2024 |
| Oren Livnat HC Wainwright & Co. | Buy | $87 | Maintains | May 13, 2024 |
| Vamil Divan Guggenheim | Buy | $77 | Reiterates | Apr 23, 2024 |
| Timothy Chiang Capital One | Overweight | Initiates | Mar 15, 2024 | |
| Vamil Divan Guggenheim | Buy | $77 | Maintains | Mar 5, 2024 |
| Oren Livnat HC Wainwright & Co. | Buy | $83 | Maintains | Mar 4, 2024 |
| Gregory Fraser Truist Securities | Buy | $80 | Maintains | Mar 1, 2024 |
| Gregory Fraser Truist Securities | Buy | $72 | Maintains | Feb 16, 2024 |
| Vamil Divan Guggenheim | Buy | $72 | Reiterates | Oct 19, 2023 |
| Vamil Divan Guggenheim | Buy | $72 | Reiterates | Sep 13, 2023 |
HC Wainwright & Co. | Buy | Maintains | Aug 22, 2023 | |
Truist Securities | Buy | Reiterates | Aug 21, 2023 | |
Guggenheim | Buy | Maintains | Aug 10, 2023 |
When did it IPO
2000
Staff Count
642
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Mr. Nikhil Lalwani
Market Cap
$1.22B
In 2023, ANIP generated $486.8M in revenue, which was a increase of 53.87% from the previous year. This can be seen as a signal that ANIP's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 02 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks uses the Zacks Rank system, focusing on earnings estimates and revisions, while also monitoring value, growth, and momentum trends to identify strong stock picks.
Why It Matters - Zacks emphasizes earnings estimates and revisions, which can signal stock performance. Monitoring value, growth, and momentum trends can lead to identifying high-potential investment opportunities.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - ANI Pharmaceuticals' CEO Nikhil Lalwani and CFO Stephen Carey will speak at the 36th Annual Piper Sandler Healthcare Conference on December 4, 2024, at 3 PM EST in NYC.
Why It Matters - The announcement of a fireside chat indicates ANI Pharmaceuticals is engaging with investors, potentially revealing insights on company strategy and financial health, influencing stock performance.
Tue, 26 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - ANI (ANIP) has a consensus price target indicating a 31.3% upside potential. Additionally, upward earnings estimate revisions suggest possible near-term stock gains.
Why It Matters - A 31.3% upside potential suggests significant growth opportunity for ANI (ANIP), while rising earnings estimates indicate positive momentum, potentially boosting investor confidence.
Wed, 20 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy) due to increasing optimism about its earnings prospects, suggesting potential for upward movement in its stock.
Why It Matters - The upgrade to Zacks Rank #2 signals increased confidence in ANI's earnings potential, likely attracting investor interest and driving the stock price higher.
Thu, 14 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks emphasizes its Rank system, focusing on earnings estimates and revisions to identify strong stocks, while also monitoring value, growth, and momentum trends.
Why It Matters - The emphasis on earnings estimates and revisions highlights potential stock performance, guiding investors toward promising opportunities based on fundamental analysis.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - ANI Pharmaceuticals will hold its Q3 2024 earnings conference call on November 8, 2024, at 8:00 AM ET, featuring key executives and analysts from major financial firms.
Why It Matters - The ANI Pharmaceuticals Q3 earnings call provides insights into financial performance and strategic direction, critical for assessing investment potential and market confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
